Stockscreener 앱 받기
33.62
2.15%
-0.74
시장 영업 전:
33.80
0.18
+0.54%
전일 마감가:
$34.36
열려 있는:
$34.36
하루 거래량:
723.76K
Relative Volume:
0.79
시가총액:
$2.61B
수익:
$688.00K
순이익/손실:
$-170.19M
주가수익비율:
-11.02
EPS:
-3.0495
순현금흐름:
$-154.68M
1주 성능:
+0.51%
1개월 성능:
+43.49%
6개월 성능:
+89.84%
1년 성능:
+40.55%
1일 변동 폭
$33.24
$35.17
1주일 범위
$33.24
$35.31
52주 변동 폭
$10.91
$35.31
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
33.62 | 2.67B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
60,372,927 Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series A Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series B Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Spyre Therapeutics stock hits 52-week high at 35.0 USD - Investing.com
Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighShould You Buy? - MarketBeat
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring - inkl
Affinity Asset Advisors LLC Raises Stock Holdings in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics (NASDAQ: SYRE) issues 20,300-share inducement stock options - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2%Still a Buy? - MarketBeat
Spyre Therapeutics CEO Turtle Cameron sells $435k in stock By Investing.com - Investing.com UK
Spyre Therapeutics: A New Era Unfolds? - timothysykes.com
A significant driver of top-line growth: Spyre Therapeutics Inc (SYRE) - setenews.com
Spyre Therapeutics stock reaches 52-week high at 30.56 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock reaches 52-week high at 30.56 USD - Investing.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulation2025 Valuation Update & Fast Exit and Entry Trade Guides - Newser
Why Spyre Therapeutics Inc. stock is in analyst buy zone2025 AllTime Highs & Detailed Earnings Play Strategies - Newser
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating - MarketBeat
What is the fair value of Spyre Therapeutics Inc. stock nowRate Hike & Verified Momentum Stock Watchlist - Newser
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to “Buy” Rating - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High After Analyst Upgrade - Defense World
Can Spyre Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Jones Trading Upgrades Spyre Therapeutics (SYRE) - Nasdaq
SYRE Stock Upgraded by Jones Trading; New Price Target Set at $6 - GuruFocus
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Franklin Resources Inc. - MarketBeat
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC - Defense World
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Geode Capital Management LLC - MarketBeat
Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential - Investing.com Canada
Nasdaq Composite Tracks Rising Biotech Momentum At Spyre Therapeutics - Kalkine Media
What analysts say about Spyre Therapeutics Inc 3920 stockFundamental Stock Analysis & Big Returns Low Cost - earlytimes.in
Spyre Therapeutics, Inc. $SYRE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
A Look at Spyre Therapeutics Inc (SYRE) Shares in the Recent Past Indicates Growth - Setenews
Spyre Therapeutics stock hits 52-week high at 29.1 USD By Investing.com - Investing.com South Africa
Spyre Therapeutics stock hits 52-week high at 29.1 USD - Investing.com India
Why Spyre Therapeutics Inc. (3920) stock benefits from AI revolutionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Spyre Therapeutics Inc. stock deliver strong Q4 earningsMarket Movers & Fast Entry High Yield Tips - newser.com
Is Spyre Therapeutics Inc. (3920) stock worth buying before Fed actionTrend Reversal & Daily Stock Momentum Reports - newser.com
Top investors say Spyre Therapeutics Inc (SYRE) ticks everything they need - Setenews
Earnings visualization tools for Spyre Therapeutics Inc. - newser.com
Will Spyre Therapeutics Inc. (3920) stock recover faster than industryJuly 2025 Patterns & Fast Entry and Exit Trade Plans - newser.com
Using data tools to time your Spyre Therapeutics Inc. exit2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Backtesting results for Spyre Therapeutics Inc. trading strategiesQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Will Spyre Therapeutics Inc. (3920) stock announce special dividend2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):